Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Momenta initiated with an Equal Weight at Barclays


Teva upgraded to Buy from Neutral at Goldman:

Goldman Sachs analyst Jami Rubin upgraded Teva Pharmaceuticals (TEVA) to Buy saying the setup for 2016 is attractive following the pullback in shares that began in late July. Several share overhangs will be removed in the near-term, with a likely equity offering ahead of Allergan (AGN) genetics unit purchase and recent quantification of Copaxone generic downside risk, Rubin tells investors in a research note. The analyst keeps a $75 price target for Teva.